Related references
Note: Only part of the references are listed.Access to High-Cost Biological Agents: Perceptions of Brazilian Patients with Inflammatory Bowel Diseases
Rogerio Serafim Parra et al.
JOURNAL OF CLINICAL MEDICINE (2023)
A Multicentre Study of the Clinical and Epidemiological Profile of Inflammatory Bowel Disease in Northeast Brazil
Carlos Alexandre Antunes de Brito et al.
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2023)
IBD barriers across the continents: a continent-specific analysis: Latin America
Natalia Sousa Freitas Queiroz et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2023)
Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis
Yong Il Lee et al.
GUT AND LIVER (2021)
The four epidemiological stages in the global evolution of inflammatory bowel disease
Gilaad G. Kaplan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study
A. B. Quaresma et al.
JOURNAL OF CROHNS & COLITIS (2021)
Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review
Paulo Gustavo Kotze et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
Javier P. Gisbert et al.
JOURNAL OF CROHNS & COLITIS (2020)
Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis
Jean-Frederic Colombel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study
Roy Frei et al.
JOURNAL OF CROHNS & COLITIS (2019)
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
Nicholas A. Kennedy et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study
Levente Parragi et al.
JOURNAL OF CROHNS & COLITIS (2018)
Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis
K. Papamichael et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Cohort Profile: The Inflammatory Bowel Disease South Limburg Cohort (IBDSL)
Tim R. A. van den Heuvel et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2017)
Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients
L. Angelison et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
Fernando Gomollon et al.
JOURNAL OF CROHNS & COLITIS (2017)
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Marisa Iborra et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Understanding and Preventing the Global Increase of Inflammatory Bowel Disease
Gilaad G. Kaplan et al.
GASTROENTEROLOGY (2017)
Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window
Konstantinos Papamichael et al.
INFLAMMATORY BOWEL DISEASES (2017)
P623 Therapeutic preferences and outcomes in newly diagnosed patient with inflammatory bowel diseases in the biological era in Hungary. A nationwide study based on the National Health Insurance Fund database
L. Gonczi et al.
Journal of Crohns & Colitis (2017)
Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study
Masanao Nasuno et al.
DIGESTION (2017)
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Uri Kopylov et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed
J. P. Gisbert et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease
Thomas Billiet et al.
JOURNAL OF CROHNS & COLITIS (2015)
High-Dose Infliximab Therapy in Crohn's Disease: Clinical Experience, Safety, and Efficacy
Steven A. Hendler et al.
JOURNAL OF CROHNS & COLITIS (2015)
Early Intervention with Adalimumab May Contribute to Favorable Clinical Efficacy in Patients with Crohn's Disease
Jun Miyoshi et al.
DIGESTION (2014)
Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
Omoniyi J. Adedokun et al.
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Clinical Efficacy of lnfliximab in Moderate to Severe Ulcerative Colitis in a Latin American Referral Population
Fabian Juliao et al.
DIGESTION (2013)
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response
Lior Katz et al.
INFLAMMATORY BOWEL DISEASES (2012)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease
Matthias Jurgens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
Adedigbo A. Fasanmade et al.
CLINICAL THERAPEUTICS (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose Escalation in Patients Losing Response
Maria Chaparro et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2011)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cohort Profile: The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)
Valerie Pittet et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2009)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Long-term outcome after infliximab for refractory ulcerative colitis
Marc Ferrante et al.
JOURNAL OF CROHNS & COLITIS (2008)
The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies
Erik von Elm et al.
PLOS MEDICINE (2007)
Infliximab dose intensification in Crohn's disease
Miguel Regueiro et al.
INFLAMMATORY BOWEL DISEASES (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study
A Orlando et al.
DIGESTIVE AND LIVER DISEASE (2005)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
